Home | Meeting coverage | ESMO 2021

Most viewed

ESMO 2021

Daniel Shao-Weng Tan, MD

VGEF antibody plus TKI: the conundrum continues

BEVERLY, WJOG971L

ESMO 2021

Hope Rugo, MD

T-Dxd: New treatment paradigm for patients with...

DESTINY-Breast03

ESMO 2021

Javier Cortes, MD

T-Dxd - a new standard for 2nd line HER2+ MBC

Destiny-Breast03

ESMO 2021

Sara Tolaney, MD

First study to report OS benefit with CDK4/6i in first...

MONALEESA-02:

ESMO 2021

Axel Hauschild, MD

Pembrolizumab adjuvant in stage II reduces the risk of...

KEYNOTE-716

ESMO 2021

Michael Thomas, MD

Chemoimmunotherapy in 1st line is getting crowded

POSEIDON

ESMO 2021

Eleni Efstathiou MD

The game changer: Abiraterone in high risk M0 prostate...

STAMPEDE

ESMO 2021

Lizza Hendriks, MD

PORT: is the discussion really closed?

lung ART

ESMO 2021

Marc-Oliver Grimm, MD

Long-term survival with double checkpoint-inhibition

CheckMate-214

ESMO 2021

Georgina Long, MD

My ESMO melanoma highlights

KEYNOTE-716, RELATIVITY-047, COLUMBUS

ESMO 2021

Tom Powles, MD

ESMO highlights: Spacing out Ipi; TKI drug holidays,...

PRISM, STAR, KEYNOTE-564

Breast Cancer metastatic: Discussions

ESMO 2021

M. Untch, N. Harbeck, B. Pistilli, A. Gennari, J. Cortes, G. Curigliano, S. Tolaney

DESTINY Breast03: T-Dxd - a new standard for HER2+ MBC

DESTINY-Breast03

ESMO 2021

M. Untch, V. Müller, N. Harbeck, A. Gennari, S. Tolaney, J. Cortes, B. Pistilli, G. Curigliano

MONALEESA-2: Long Term 1st Line significant overall...

MONALEESA-02

ESMO 2021

V. Müller, N. Harbeck, B. Pistilli, A. Gennari, J. Cortes, G. Curigliano, S. Tolaney

KEYNOTE-355: Pembrolizumab A new option for TNBC

KEYNOTE-355

Breast Cancer metastatic

ESMO 2021

Hope Rugo, MD

Remarkable improvement of overall survival with...

MONALEESA-2

ESMO 2021

Hope Rugo, MD

T-Dxd: New treatment paradigm for patients with...

DESTINY-Breast03

ESMO 2021

Sara Tolaney, MD

New standard of care for HER2+ MBC

DESTINY-Breast03

ESMO 2021

Peter A. Fasching, MD

Ribociclib in 1st line: Long follow-up time confirms OS...

MONALEESA-2

ESMO

Michael Untch, MD

Two positive trials reinforce the role of...

KEYNOTE355, KEYNOTE-522

ESMO 2021

Michael Untch, MD

Remarkable survival benefit with Ribociclib defines a...

Monaleesa-02

ESMO 2021

Karen Gelmon, MD

MBC significant data: T-Dxd, Pembrolizumab, Ribciclib

KEYNOTE-355, DESTINY Breast03, MONALEESA-2

ESMO 2021

Gil Morgan, MD

Becoming the standard of care for patients with HER2+...

DESTINY-Breast03

ESMO 2021

Elzbieta Senkus-Konefka, MD

Finally a survival benefit in 1st line metastatic TNBC

KEYNOTE-355

ESMO 2021

Hope Rugo, MD

A new standard of care for TNBC

KEYNOTE-355

ESMO 2021

Sara Tolaney, MD

First study to report OS benefit with CDK4/6i in first...

MONALEESA-02:

ESMO 2021

Elzbieta Senkus-Konefka, MD

Large step forward in HER2+ MBC with T-Dxd

DESTINY-Breast03

ESMO 2021

Sara Tolaney, MD

Survival data confirm pembrolizumab as standard of care

KEYNOTE-355

ESMO 2021

Volkmar Müller, MD

Management of Carcinomatous Meningitis (CM) in breast...

Carcinomatous Meningitis

ESMO 2021

Volkmar Müller, MD

Dose escalation of everolimus in patients with...

DESIREE

ESMO 2021

Volkmar Müller, MD

Great results and further research

DESTINY-BREAST03, DEBRAH, DESTINY-Breast12, TUXEDO-1

ESMO 2021

Giuseppe Curigliano, MD

ESMO21 highlights in metastatic and early breast cancer

DESTINY-BREAST03, KEYNOTE-355, BrightNess

ESMO 2021

Javier Cortes, MD, PhD

T-Dxd - a new standard for 2nd line HER2+ MBC

Destiny-Breast03

ESMO 2021

Peter A. Fasching, MD

T-DXd: Impressive results show the potential of ADC...

DESTINY-Breast03

ESMO 2021

Barbara Pistilli, MD

Impressive new data on the improvement of PFS with...

Destiny-Breast03

Breast Cancer Metastatic: Multi-Language

ESMO 2021

Peter A. Fasching, MD

Ribociclib in 1st line: Lange Nachbeobachtungszeit...

MONALEESA-2

ESMO 2021

Elzbieta Senkus-Konefka, MD

Krok milowy w leczeniu zaawansowanego, HER2-dodatniego...

DESTINY-Breast03

ESMO 2021

Giuseppe Curigliano, MD

Punti salienti nel carcinoma mammario metastatico e...

DESTINY-BREAST03, KEYNOTE-355, BrightNess

ESMO 2021

Javier Cortes, MD, PhD

T-DXd: un nuevo estándar de tratamiento en pacientes...

Destiny-Breast03

ESMO 2021

Barbara Pistilli, MD

Dés résultats impressionnants avec les T-DXd en 2ème...

Destiny-Breast03

ESMO 2021

Peter A. Fasching, MD

T-DXd: Beeindruckende Ergebnisse zeigen Potenzial der...

DESTINY-Breast03

ESMO 2021

Barbara Pistilli, MD

Risultati straordinari con il T-DXd in seconda linea...

Destiny-Breast03

ESMO 2021

Elzbieta Senkus-Konefka, MD

Nareszcie wydłużenie całkowitego czasu przeżycia w 1....

KEYNOTE-355

ESMO 2021

Michael Untch, MD

Doua trialuri pozitive in tratamentului imunoonologic...

KEYNOTE355, KEYNOTE-522

ESMO 2021

Michael Untch, MD

Beneficiu ramarcabil cu Ribociclib in prima linie de...

Monaleesa-02

Breast Cancer early: Discussions

ESMO 2021

R. Dent, K. Gelmon, E. Senkus-Konefka, V. Müller, M. Untch, H. Rugo

HER2+: Reduced duration of adjuvant Trastuzumab

HER2+ Meta-Analyses

ESMO 2021

R. Dent, K. Gelmon, E. Senkus-Konefka, V. Müller, M. Untch, H. Rugo

TNBC: Carboplatinum in neoadjuvant therapy

BrighTNess

ESMO 2021

R. Dent, K. Gelmon, E. Senkus-Konefka, V. Müller, M. Untch, H. Rugo

TNBC: CPI performing in the neo-adjuvant setting

KEYNOTE-522

Breast Cancer early

ESMO 2021

Karen Gelmon, MD

TNBC Benefit: Pembro + NACT; Carboplatinum

KEYNOTE-522, BrighTNess

ESMO 2021

Peter A. Fasching, MD

Shortening the trastuzumab therapy to 6 months?

ESMO 2021

Alessandra Gennari, MD, PhD

Extended adjuvant Letrozole with significant DFS...

GIM4

ESMO 2021

Nadia Harbeck, MD

High risk patients deserve Pembro

KEYNOTE-522

ESMO 2021

Nadia Harbeck, MD

Patient selection allows efficacy and deescalation

WSG ADAPT TP

ESMO 2021

Elzbieta Senkus-Konefka, MD, PhD

Carboplatin, a new standard of care in early TNBC?

BrighTNess

ESMO 2021

Alessandra Gennari, MD, PhD

Addition of Carbo-Platin with signifcant EFS advantage

BrighTNess

ESMO 2021

Peter A. Fasching, MD

Neoadjuvant Giredestrant showed anti-proliverative...

coopERA BC

ESMO 2021

Nadia Harbeck, MD

Trastuzumab + Lapatinib; reducing the duration of...

HER2 - Metaanalysen

Breast Cancer early: Multi-Language

ESMO 2021

Peter A. Fasching, MD

Verkürzung der Trastuzumab-Therapie auf 6 Monate?

ESMO 2021

ESMO 2021

Peter A. Fasching, MD

Giredestrant zeigt anti-proliverative Wirkung im...

coopERA BC

ESMO 2021

Alessandra Gennari, MD, PhD

Estensione del letrozolo adiuvante con vantaggio...

GIM4

ESMO 2021

Alessandra Gennari, MD, PhD

Aggiunta di carboplatino neoadiuvante con vantaggio...

BrighTNess

ESMO 2021

Nadia Harbeck, MD

Pembrolizumab - eine Option für high risk Pat.

KEYNOTE-522

ESMO 2021

Nadia Harbeck, MD

Trastuzumab: Kombination mit Lapatinib und verkürzte...

HER2 - Metaanalysen

ESMO 2021

Nadia Harbeck, MD

Patientenselektion mit hoher Wirksamkeit und...

WSG ADAPT TP

ESMO 2021

Elzbieta Senkus-Konefka, MD, PhD

Karboplatyna – nowy standard leczenia we wczesnym,...

BrighTNess

NSCLC metastatic: Discussions

ESMO 2021

F. Griesinger, M. Reck, M. Thomas, N. Reguart, N. Girard, A. Addeo, D. SW Tan, M. Hellmann, H. Borghaei

Upcoming therapy options in oncogenic-driven NSCLC

DESTINY-Lung01, TROPION, ZENITH20-4

ESMO 2021

F. Griesinger, M. Reck, M. Thomas, N. Reguart, N. Girard, A. Addeo, D. SW Tan, M. Hellmann, H. Borghaei

BFAST: The Challenge of new biomarkers for...

BFAST

ESMO 2021

F. Griesinger, M. Reck, M. Thomas, N. Reguart, N. Girard, A. Addeo, D. SW Tan, M. Hellmann, H. Borghaei

IO combinations in advanced NSCLC - revolution and...

EMPOWER-Lung 3, POSEIDON, other

NSCLC Metastatic

ESMO 2021

Noemi Reguart, MD, PhD

New options for 2nd line after IO-failure

Atalante-1, MRTX-500

ESMO 2021

Lizza Hendriks, MD

Are vaccines the way forward after progressing on...

LBA47

ESMO 2021

Matthew D. Hellmann, MD

New opportunitiy to treat HER2-mutated lung cancer

DESTINY-Lung01

ESMO 2021

Daniel Shao-Weng Tan, PhD

VGEF antibody plus TKI: the conundrum continues

BEVERLY, WJOG971L

ESMO 2021

Noemi Reguart, MD, PhD

New options in salvage setting for EGFR-mutant patients

TROPION-PanTumor01, CHRYSALIS, CHRYSALIS-2

ESMO 2021

Hossein Borghaei, MD

EGFR TKI plus VEGF inhibition

BEVERLY

ESMO 2021

Hossein Borghaei, MD

Potential new biomarker for immunotherapy

BFAST

ESMO 2021

Denis Moro-Sibilot, MD

A new treatment for HER2-mutated NSCLC

DESTINY-Lung01

ESMO 2021

Lizza Hendriks, MD

KRASG12C and platinum doublet chemotherapy: does the...

NVALT22

ESMO 2021

Michael Thomas, MD

Chemoimmunotherapy in 1st line is getting crowded

POSEIDON

ESMO 2021

Denis Moro-Sibilot, MD

Failure to demonstrate PFS-improvement when combining...

WJOG9717L study

ESMO 2021

Nicolas Girard, MD

Trastuzumab Deruxtecan, a new option for HER2+ lung...

DESTINY-Lung01

ESMO 2021

Michael Thomas, MD

HER2 mutations: new opportunities effective

DESTINY-Lung01, ZENITH20-4

ESMO 2021

Christian Grohé, MD

Gavo-cel dose escalation in refractory...

ESMO 2021

Frank Griesinger, MD, PhD

New ADC for lung cancer

TROPION-PanTumor01

ESMO 2021

Frank Griesinger, MD, PhD

Cemiplimab + chemotherapy: 1st presentation of...

EMPOWER-Lung3

ESMO 2021

Daniel Shao-Weng Tan, PhD

New 1st line option

EMPOWER-Lung3

ESMO 2021

Hossein Borghaei, MD

2nd line option after IO failure

MRTX-500

ESMO 2021

Stephen Liu, MD

Poziotinib in HER2 mutated lung cancer

ZENITH20-4

NSCLC Metastatic: Multi-Language

ESMO 2021

Noemi Reguart, MD, PhD

Nuevas terapias en linea avanzada de pacientes con...

TROPION-PanTumor01, CHRYSALIS, CHRYSALIS-2

ESMO 2021

Denis Moro-Sibilot, MD

Absence d'amélioration de la SSP en associant le...

Étude WJOG9717L

ESMO 2021

Michael Thomas, MD

HER2 Mutation: Drug-Immuno-Conjugates effektiv

DESTINY-Lung01, ZENITH20-4

ESMO 2021

Nicolas Girard, MD

le TdxD, nouvelle option pour les CBNPC HER2+?

DESTINY-Lung01

ESMO 2021

Noemi Reguart, MD, PhD

Nuevas opciones terapéuticas en segunda linea tras...

Atalante-1, MRTX-500

ESMO 2021

Frank Griesinger, MD, PhD

Neues AWK beim Lungenkarzinom

TROPION-PanTumor01

ESMO 2021

Frank Griesinger, MD, PhD

Cemilimab + Chemotherapie: Erste Daten der...

EMPOWER-Lung3

ESMO 2021

Christian Grohé, MD

CAR-T-Zell-Therapie auch bei refraktären...

ESMO 2021

Martin Reck, MD

Kein Vorteil für Anti-IL1 AK

ESMO 2021

Denis Moro-Sibilot, MD

Un nouveau traitement pour le CBNPC HER2-muté

DESTINY-Lung01

ESMO 2021

Michael Thomas, MD

Chemoimmuntherapie 1st line: Wohin führt POSEIDON?

POSEIDON

NSCLC non-metastatic: Discussions

ESMO 2021

F. Griesinger, M. Reck, M. Thomas, N. Reguart, S. Liu, L. Hendriks, D. Moro-Sibilot

Immune checkpoint inhibitors - on the way to standard...

IMpower010, IONESCO

ESMO 2021

F. Griesinger, M. Reck, M. Thomas, N. Reguart, S. Liu, L. Hendriks, D. Moro-Sibilot

Stage III NSCLC - the new stage IV ?!

COAST, PACIFIC-R

NSCLC non-metastatic

ESMO 2021

Lizza Hendriks, MD

PORT: is the discussion really closed?

lung ART

ESMO 2021

Stephen Liu, MD

The benefit of adjuvant atezolizumab in PD-L1 low

IMpower010

ESMO 2021

Michael Thomas, MD

Completing the picture

IMpower010

ESMO 2021

Denis Morot-Sibilot, MD

Immunotherapy improves PFS after sequential or...

GEMSTONE-301

ESMO 2021

Nicolas Girard, MD

Durvalumab consolidation in a real world setting

PACIFIC-R

ESMO 2021

Matthew D. Hellmann, MD

The power of randomization

COAST

ESMO 2021

Michael Thomas, MD

COAST on the horizon

COAST

ESMO 2021

Frank Griesinger, MD, PhD

Endpoint pathological response in induction therapy...

IONESCO

ESMO 2021

Frank Griesinger, MD, PhD

Update on IMpower010

IMpower010

ESMO 2021

Alfredo Addeo, MD

New option in unresectable NSCLC?

COAST

ESMO 2021

Daniel Shao-Weng Tan, PhD

Wind of change?

IMpower010

ESMO 2021

Stephen Liu, MD

Update on chemoradiation for stage III NSCLC

PACIFIC-R, COAST, GEMSTONE-301

ESMO 2021

Matthew D. Hellmann, MD

Inflection point in next generation drug development

GEMSTONE-301

ESMO 2021

Michael Thomas, MD

IO mono-Induction: window of opportunity to guide...

IONESCO, LCMC3

ESMO 2021

Gil Morgan, MD

Potential new standard of care in NSCLC

DESTINY-Lung01

NSCLC non-metastatic: Multi-Language

ESMO 2021

Lizza Hendriks, MD

Zijn vaccins de toekomst na progressie op...

Atalante-1

ESMO 2021

Michael Thomas, MD

Neue Horizonte durch COAST

COAST

ESMO 2021

Denis Morot-Sibilot, MD

L'immunothérapie améliore la SSP après une...

GEMSTONE-301

ESMO 2021

Lizza Hendriks, MD

KRASG12C en platinum doublet chemotherapie: maakt de...

NVALT22

ESMO 2021

Michael Thomas, MD

IO Mono Induktion - Zeitfenster für Immuntherapie

IONESCO, LCMC3

ESMO 2021

Nicolas Girard, MD

Quelle efficacité du durvalumab en pratique clinique?

PACIFIC-R

ESMO 2021

Lizza Hendriks, MD

Postoperatie radiotherapie bij N2 ziekte: is de...

lung ART

ESMO 2021

Michael Thomas, MD

Learnings from IMpower010

IMpower010

ESMO 2021

Frank Griesinger, MD, PhD

Pathological Response als Endpunkt bei...

IONECSO

ESMO 2021

Frank Griesinger, MD, PhD

Update IMpower010

IMpower010

ESMO 2021

Alfredo Addeo, MD

nouve opzioni per lo NSCLC Stadio III inoperabile?

COAST

ESMO 2021

Martin Reck, MD

Neue IO-Kombinationen vielversprechend

ESMO 2021

Martin Reck, MD

IMpower010 Update: Stellenwert von Atezolizumab...

SCLC

ESMO 2021

Noemi Reguart, MD, PhD

Update on important phase III trials

Checkmate 743, CASPIAN

ESMO 2021

Alfredo Addeo, MD

The tail matters even in ES-SCLC

CASPIAN

SCLC: Multi-Language

ESMO 2021

Noemi Reguart, MD, PhD

Actualizaciones en estudios fase III

Checkmate743, CASPIAN

ESMO 2021

Alfredo Addeo, MD

la coda conta anche nel SCLC in malattia estesa

CASPIAN

Thymoma: Discussion

ESMO 2021

F. Griesinger, M. Reck, M. Thomas, N. Reguart, N. Girard, A. Addeo, D. SW Tan, M. Hellmann, H. Borghaei

NIVOTHYM: Immunotherapy for thymic tumors

NIVOTHYM

Thymoma

ESMO 2021

Nicolas Girard, MD

Is there a role for immunotherapy for thymic tumors?

NIVOTHYM

Thymoma: Multi-Language

ESMO 2021

Nicola Girard, MD

Quelle place de l’immunothérapie pour les tumeurs...

NIVOTHYM

Mesothelioma: Discussion

ESMO 2021

F. Griesinger, M. Reck, M. Thomas, N. Reguart, S. Liu, L. Hendriks, D. Moro-Sibilot

New era in mesothelioma – stay tuned!

Checkmate 743, NCT02856425

Mesothelioma

ESMO 2021

Noemi Reguart, MD, PhD

Update on important phase III trials

Checkmate 743, CASPIAN

ESMO 2021

Alfredo Addeo, MD

IO-IO, the way to go in mesothelioma

CheckMate 743

Mesothelioma: Multi-Language

ESMO 2021

Martin Reck, MD

Langzeitüberleben durch IO

ESMO 2021

Noemi Reguart, MD, PhD

Actualizaciones en estudios fase III

Checkmate743, CASPIAN

ESMO 2021

Alfredo Addeo, MD

IO-IO, la strada da percorrere nel mesotelioma

CheckMate 744

Melanoma: Discussions

ESMO 2021

A. Hauschild, G. Long, R. Dummer, P. Ascierto, D. Schadendorf, M. Postow, P. Nathan

New data for BRAF-mutated melanoma patients

COLUMBUS, SECOMBIT

ESMO 2021

A. Hauschild, G. Long, R. Dummer, P. Ascierto, D. Schadendorf, M. Postow, P. Nathan

CheckMate 204: Brain metastases - Promising...

CheckMate 204, GEM1802/EBRAIN-MEL

ESMO 2021

A. Hauschild, G. Long, R. Dummer, P. Ascierto, D. Schadendorf, M. Postow, P. Nathan

KEYNOTE-716: Adjuvant pembrolizumab in stage IIB/C

KEYNOTE-716

ESMO 2021

A. Hauschild, G. Long, R. Dummer, P. Ascierto, D. Schadendorf, M. Postow, P. Nathan

MASTERKEY-265: Pembrolizumab +/- T-VEC

MASTERKEY-265

ESMO 2021

A. Hauschild, G. Long, R. Dummer, P. Ascierto, D. Schadendorf, M. Postow, P. Nathan

RELATIVITY-047: Subgroup updates; Enduring benefit and...

RELATIVITY-047

Melanoma

ESMO 2021

Georgina Long, MD

My ESMO melanoma highlights

KEYNOTE-716, RELATIVITY-047, COLUMBUS

ESMO 2021

Dirk Schadendorf, MD

No preference for sequential therapy

ESMO 2021

Paolo A. Ascierto, MD

ESMO 2021: updates on the SECOMBIT study

SECOMBIT

ESMO 2021

Paul Nathan, PhD

First data using immunotherapy as an adjuvant mechanism...

KEYNOTE-716

ESMO 2021

Axel Hauschild, MD

Pembrolizumab adjuvant in stage II reduces the risk of...

KEYNOTE-716

ESMO 2021

Paul Nathan, PhD

Sequencing - start with immunotherapy first

ESMO 2021

Axel Hauschild, MD

T-VEC is not a convincing partner for CPI

CheckMate 204

ESMO 2021

Paul Nathan, PhD

Personalized treatment for patients according to IFN-γ...

DONIMI

ESMO 2021

Reinhard Dummer, MD

No significant improvement

MASTERKEY-265

ESMO 2021

Dirk Schadendorf, MD

Pembrolizumab is a good option for adjuvant stage IIB/C

KEYNOTE-716

ESMO 2021

Axel Hauschild, MD

5 year update

COLUMBUS

ESMO 2021

Reinhard Dummer, MD

A 5 year update

COLUMBUS

ESMO 2021

Dirk Schadendorf, MD

Nivo/Ipi for brain metastatses

CheckMate 204

ESMO 2021

Reinhard Dummer, MD

Promising data, but some questions remain

RELATIVITY-047

ESMO 2021

Michael Postow, MD

New strategies for adjuvant stage II

KEYNOTE-716

ESMO 2021

Michael Postow, MD

Highlights from this year's ESMO

ESMO 2021

Dirk Schadendorf, MD

LAG-3-blocking ab shows benefit in combination with...

RELATIVITY-047

ESMO 2021

Michael Postow, MD

Additional efficacy and shifts in treatment options

RELATIVITY-047

Melanoma: Multi-Language

ESMO 2021

Axel Hauschild, MD

5 Jahres Update

COLUMBUS

ESMO 2021

Dirk Schadendorf, MD

Keine Präferenz bei sequenzieller Therapie

ESMO 2021

Dirk Schadendorf, MD

Nivo-Ipi bei Hirnmetastasen

CheckMate 204

ESMO 2021

Dirk Schadendorf, MD

LAG-3-AK zeigt Benefit in Kombi mit Nivo

RELATIVITY-047

ESMO 2021

Dirk Schadendorf, MD

Pembro gute Option adjuvant im Stad. IIB/C

KEYNOTE-716

ESMO 2021

Paolo A. Ascierto, MD

ESMO 2021: aggiornamenti dello studio SECOMBIT

SECOMBIT

ESMO 2021

Axel Hauschild, MD

Pembro adj. im Stad. II verringert Rezidivrisiko, aber...

KEYNOTE-716

ESMO 2021

Axel Hauschild, MD

T-VEC überzeugt nicht als Partner für CPI

CheckMate 204

Kidney Cancer: Discussions

ESMO 2021

M.-O. Grimm, P. J. Goebell, S. Chowdhury, I. Duran, H. Hammers, S. K. Pal, T. Powles

Maintaining the IO-combination with higher flexibility.

PRISM/CheckMate 214

ESMO 2021

A. S. Merseburger, M.-O. Grimm, S. Chowdhury, I. Duran, H. Hammers, S. K. Pal, T. Powles

PRO results support adjuvant IO efficacy, some...

KEYNOTE-564

Kidney Cancer

ESMO 2021

Tom Powles, MD

ESMO highlights: Spacing out Ipi; TKI drug holidays,...

PRISM, STAR, KEYNOTE-564

ESMO 2021

Hans Hammers, MD

Dual immunotherapy update

PRISM

ESMO 2021

Hans Hammers, MD

Quality of Life in adjuvant immunotherapy

KEYNOTE-564

ESMO 2021

Peter Goebell, MD

Update adjuvant immunotherapy

KEYNOTE-564

ESMO 2021

Marc-Oliver Grimm, MD

Role of cytoreductive nephrectomy in patients treated...

JAVELIN-renal101

ESMO 2021

Peter Goebell, MD

Increased flexibility for side effects due to...

PRISM

ESMO 2021

Marc-Oliver Grimm, MD

Long-term survival with double checkpoint-inhibition

CheckMate-214

ESMO 2021

Ignacio Duran, MD, PhD

HIF-2α- a promising target?

Kidney cancer: Multi-Language

ESMO 2021

Peter Goebell, MD

Höhere Flexibilität bei Nebenwirkungen durch Ipilimumab

PRISM

ESMO 2021

Axel S. Merseburger, MD

Ipi mit festem Stellenwert beim aRCC

CheckMate 214

ESMO 2021

Ignacio Duran, MD, PhD

HIF-2α - una diana prometedora?

ESMO 2021

Axel S. Merseburger, MD

Spannende Daten, wenn auch nicht "game-changing"

KEYNOTE-564

Bladder Cancer: Discussions

ESMO 2021

M.-O. Grimm, P. J. Goebell, Y. Loriot, J. Bellmunt, S. Chowdhury

VESPER: Do we have to intensify perioperative...

ESMO 2021

M.-O. Grimm, P. J. Goebell, Y. Loriot, J. Bellmunt, S. Chowdhury

NABUCCO: IPI matters – discussion on benefits in...

Bladder Cancer

ESMO 2021

Joaquim Bellmunt, MD, PhD

PD-L1 as predictor of survival in DANUBE phase III...

DANUBE

ESMO 2021

Peter Goebell, MD

Strong signal regarding PFS and OS in ddMVAC

VESPER

ESMO 2021

Joaquim Bellmunt, MD, PhD

Deciphering strategies for immunotherapy combinations

IMvigor130, AURA, NABUCCO

ESMO 2021

Peter Goebell, MD

ipilimumab-nivolumab opportunities for alternative...

NABUCCO

ESMO 2021

Joaquim Bellmunt, MD, PhD

Improving patients outcome in bladder cancer

NORSE, VESPER, Phase II Pembrolizumab in combination with sEphB4-HSA (B4)

ESMO 2021

Tom Powles, MD

ESMO highlights: new combinations FGFRa, Pembro+sEphB4,...

NORSE, VESPER

ESMO 2021

Andrea Necchi, MD

ESMO21:The highlights of Bladder cancer

VESPER, AURA, NABUCCO, NORSE

ESMO 2021

Petros Grivas, MD, PhD

VESPER neoadjuvant chemotherapy phase 3 trial in MIBC

VESPER

Bladder Cancer: Multi-Language

ESMO 2021

Peter Goebell, MD

Starkes Signal bezüglich PFS und OS bei ddMVAC

VESPER

ESMO 2021

Joaquim Bellmunt, MD, PhD

Mejorando el futuro de los pacientes con cáncer de...

NORSE, VESPER, Phase II Pembrolizumab in combination with sEphB4-HSA (B4)

ESMO 2021

Peter Goebell, MD

Ipilimumab-Nivolumab Möglichkeiten für alternative...

NABUCCO

ESMO 2021

Joaquim Bellmunt, MD, PhD

PDL-1 como predictor de supervivencia en cáncer de...

DANUBE

ESMO 2021

Andrea Necchi, MD

Novita’ in tema di tumori vescicali dal congresso ESMO...

VESPER, AURA, NABUCCO, NORSE

ESMO 2021

Joaquim Bellmunt, MD, PhD

Descifrando las estrategias para mejorar las...

IMvigor130, AURA, NABUCCO

Prostate Cancer: Discussions

ESMO 2021

E. Efstathiou, A. S. Merseburger, S. Chowdhury, N. Shore, P. Goebell, M.-O. Grimm, A. Bjartell, G. Morgan

COSMIC-021: mCRPC perspectives in later Lines.

ESMO 2021

A. S. Merseburger, E. Efstathiou, S. Chowdhury, N. Shore, A. Bjartell, G.Morgan, P. Goebell, M.-O. Grimm

ARCHES & PEACE-1: From doublets to triplets in mHSPC?

ESMO 2021

A. S. Merseburger, S. Chowdhury, N. Shore, E. Efstathiou, A. Bjartell, P. Goebell, M.-O. Grimm

STAMPEDE: Practice changing in high-risk non-metastatic...

Prostate cancer

ESMO 2021

Axel S. Merseburger, MD

Hope for patients with mCRPC

COSMIC-021

ESMO 2021

Eleni Efstathiou MD

The game changer: Abiraterone in high risk M0 prostate...

STAMPEDE

ESMO 2021

Anders Bjartell, MD, PhD

Survival benefit with triplet therapy for mHSPC

PEACE-01

ESMO 2021

Anders Bjartell, MD, PhD

New data change our practice in non-metastatic...

STAMPEDE

ESMO 2021

Axel S. Merseburger, MD

More data for extending Enzalutamide's label for mHSPC

ARCHES

ESMO 2021

Simon Chowdhury, MD, PhD

Is it really practice changing?

PEACE-01

ESMO 2021

Simon Chowdhury, MD, PhD

Significant advances in M0 PCa

STAMPEDE

ESMO 2021

Simon Chowdhury, MD, PhD

DS7300 - an exciting novel therapy in prostate cancer...

DS-7300

ESMO 2021

Eleni Efstathiou MD

mHSPC: ADT alone is not enough!

PEACE-1, ARCHES

ESMO 2021

Neal Shore, MD

DD-MVAC is the new SOC!

VESPER

ESMO 2021

Petros Grivas, MD, PhD

STAMPEDE trial: new standard of care for localized high...

STAMPEDE

ESMO 2021

Petros Grivas, MD, PhD

PEACE-1 phase 3 trial in metastatic CSPC

PEACE-01

ESMO 2021

Neal Shore, MD

Is triplet therapy the new SOC?

PEACE-01

ESMO 2021

Peter Goebell, MD

Triplet or duplet for high-risk patients

STAMPEDE

ESMO 2021

Neal Shore, MD

PSMA – RLT is here!

ESMO 2021

Anders Bjartell, MD, PhD

Combination therapies and new targeted therapies in...

ESMO 2021

Peter Goebell, MD

New promising Combination with Pembro and lu-PSMA

PRINCE

ESMO 2021

Anders Bjartell, MD, PhD

Enzalutamide added to ADT shows clear survival benefit...

ARCHES

ESMO 2021

Gil Morgan, MD

Practice changing results for mHSCP

PEACE-01

ESMO 2021

Axel S. Merseburger, MD

Chemo Upront: Consider combination with Abiraterone

PEACE-1

Prostate cancer: Multi-Language

ESMO 2021

Anders Bjartell, MD

PEACE-1 studien visar överlevnadsvinst med trippel...

PEACE-1

ESMO 2021

Peter Goebell, MD

Neue vielversprechende Kombination mit Pembro und...

PRiNCE

ESMO 2021

Anders Bjartell, MD

Resultat från STAMPEDE öppnar för ny...

STAMPEDE

ESMO 2021

Axel S. Merseburger, MD

Ein weiteres Puzzlestück für Zulassungserweiterung von...

ARCHES

ESMO 2021

Anders Bjartell, MD

Längre uppföljningstid I ARCHES-studien visar klar...

ARCHES

ESMO 2021

Axel S. Merseburger, MD

Hoffnung für Patienten mit mCRPC

COSMIC-021

ESMO 2021

Eleni Efstathiou, MD

Μεταστατικός ορμόνο ευαίσθητος καρκίνος προστάτη: Η...

PEACE-1, ARCHES

ESMO 2021

Eleni Efstathiou, MD

Σημαντικό όφελος με την προσθήκη άμπιρατερονης Στην...

STAMPEDE

ESMO 2021

Anders Bjartell, MD

Kombinationsbehandlingar och nya riktade terapier vid...

ESMO 2021

Axel S. Merseburger, MD

Chemo Upfront: Kombination mit Abiraterone bedenken!

PEACE-1

ESMO 2021

Peter Goebell, MD

Triplet oder Duplette beim hochrisiko Patienten

STAMPEDE

Cross Tumor Topics

ESMO 2021

Petros Grivas, MD, PhD

Covid19 & Cancer: updates from ESMO 2021

ESMO 2021

Christian Grohé, MD

CAR-T-Zell-Therapie auch bei refraktären...